From WikiProjectMed
Jump to navigation Jump to search
Trade namesVivjoa
Other namesVT-1161
  • (2R)-2-(2,4-Difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol
Clinical data
Drug classAntifungal
Main usesRecurrent vaginal yeast infections[1]
Side effectsHeadache, nausea[1]
  • Contraindicated[2]
Routes of
By mouth
External links
License data
Legal status
Chemical and physical data
Molar mass527.403 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
  • InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1

Oteseconazole, sold under the brand name Vivjoa, is a medication used to decrease the frequency of recurrent vaginal yeast infections.[1] It is taken by mouth.[1] It may be used with fluconazole.[1]

Commons side effects include headache and nausea.[1] Use within two years of pregnancy may harm the baby and thus it should not be used in women who could become pregnant.[1] Use is not recommended in those with significant kidney or liver problems.[1] It is a 14α-demethylase (CYP51) inhibitor.[4]

Oteseconazole was approved for medical use in the United States in 2022.[1] It is not approved in Europe or the United Kingdom as of 2022.[4] In the United States a course of treatment costs about 2,900 USD as of 2022.[5]

Medical use


It is initially taken at a dose of 600 mg followed by 450 mg the next day.[1] Starting on day 14 it is than taken at a dose of 150 mg once per week for 11 weeks.[1]

Society and culture

It was developed by Mycovia Pharmaceuticals.[6]


Oteseconazole is the international nonproprietary name (INN).[7]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "DailyMed - VIVJOA- oteseconazole capsule". dailymed.nlm.nih.gov. Archived from the original on 13 August 2022. Retrieved 12 December 2022.
  2. "Oteseconazole (Vivjoa) Use During Pregnancy". Drugs.com. Retrieved 12 December 2022.
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf Archived 2022-05-23 at the Wayback Machine[bare URL PDF]
  4. 4.0 4.1 "Oteseconazole". SPS - Specialist Pharmacy Service. 3 April 2021. Archived from the original on 8 August 2022. Retrieved 12 December 2022.
  5. "Vivjoa Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 12 December 2022.
  6. "FDA Approves Mycovia Pharmaceuticals' VIVJOA (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)" (Press release). Mycovia Pharmaceuticals. 28 April 2022. Archived from the original on 28 April 2022. Retrieved 28 April 2022 – via Business Wire.
  7. World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3). hdl:10665/331020.

External links

External sites: